Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 04:55 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Rivaroxaban vs Warfarin in Patients With Metallic Prosthesis
NCT03566303 · Hospital Geral Roberto Santos · PHASE2/PHASE3 · terminated · last registry update 2020-05-15 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Coronavirus Pandemic” | – | Registry record, Hospital Geral Roberto Santos |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against F10 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2021-04-30Phase 3 first posted: Octapharma, Octaplex (NCT04867837)
- 2021-01-29Phase 3 first posted: Kyushu University, Edoxaban + Warfarin Potassium (NCT04730037)
- 2020-12-02Phase 3 first posted: Thomas L. Ortel, Apixaban 2.5 MG + Placebo (NCT04650087)
- 2020-09-24Phase 3 first posted: Emory University, Emicizumab + FEIBA (NCT04563520)
- 2020-06-16Phase 3 first posted: Hoffmann-La Roche, Emicizumab (NCT04431726)
- 2020-03-27Phase 3 first posted: Population Health Research Institute, Colchicine + Interferon-Beta (NCT04324463)
- 2020-02-26Phase 3 first posted: Population Health Research Institute, DOAC + VKA (NCT04284839)
- 2020-02-18Phase 3 first posted: Mazandaran University of Medical Sciences, Rivaroxaban 2.5 Mg Oral Tablet + Rivaroxaban placebo tablets (NCT04273516)
- 2019-11-12Phase 3 first posted: Hoffmann-La Roche, Emicizumab (NCT04158648)
- 2019-10-29Phase 3 first posted: Artivion Inc., Apixaban 5 MG + Apixaban 2.5 MG (NCT04142658)
- 2019-10-29Phase 3 first posted: Population Health Research Institute, Rivaroxaban 2.5 Mg Oral Tablet bid + Acetylsalicyclic acid 81 mg tablet qd (NCT04142125)
- 2019-08-30Phase 3 first posted: Sudeep Shivakumar, Rivaroxaban 10 MG and acetylsalicylic acid 81 mg + acetylsalicylic acid 81 mg (NCT04075240)
- 2019-08-26Phase 3 first posted: Second Affiliated Hospital, Zhejiang University, School of Medicine, Rivaroxaban + Warfarin (NCT04067505)
- 2019-08-26Phase 3 first posted: Second Affiliated Hospital, Zhejiang University, School of Medicine, Rivaroxaban + Warfarin (NCT04066764)
- 2019-08-05Phase 3 first posted: Icahn School of Medicine at Mount Sinai, Antiplatelet-only strategy + Oral Anticoagulant plus background antiplatelet therapy (NCT04045665)
- 2019-07-23Phase 3 first posted: Emory University, Nuwiq (low dose protocol) + HEMLIBRA (NCT04030052)
- 2019-07-05Phase 3 first posted: Assistance Publique - Hôpitaux de Paris, Apixaban + Placebo (NCT04007289)
- 2019-06-25Phase 3 first posted: Imperial College London, Apixaban Oral Tablet + Dabigatran (NCT03996772)
- 2019-05-31Phase 3 first posted: The George Institute, Rivaroxaban 2.5 Mg Oral Tablet (NCT03969953)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision